Literature DB >> 2857210

Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.

A Dornhorst, S H Powell, J Pensky.   

Abstract

14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period. Hydrochlorothiazide significantly increased fasting glucose by 31% (p less than 0.05) and glycosylated haemoglobin (HbA1c) by 6.0% (p less than 0.10). A similar treatment period of propranolol 80 mg twice a day caused no significant increases. However, when both drugs were taken in combination, fasting glucose rose by 56% and HbA1c by 14.7% (p less than 0.01). The hyperglycaemic effect of hydrochlorothiazide and its potentiation by propranolol were independent of serum potassium and of endogenous insulin secretion as measured by urine C-peptide excretion. The combination of hydrochlorothiazide and propranolol thus seems to cause serious disturbances in glycaemic control in type II diabetics by mechanisms independent of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857210     DOI: 10.1016/s0140-6736(85)91900-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

Review 1.  Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).

Authors:  S O'Byrne; J Feely
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

2.  Clinical trials report. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension.

Authors:  Kathleen H Berecek; David Calhoun
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

3.  Effect of oral verapamil on glibenclamide stimulated insulin secretion.

Authors:  C G Semple; C Omile; K D Buchanan; G H Beastall; K R Paterson
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

Review 4.  Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice.

Authors:  S Vijan; D L Stevens; W H Herman; M M Funnell; C J Standiford
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

5.  Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.

Authors:  Andrew R Zullo; Michelle Hersey; Yoojin Lee; Sadia Sharmin; Elliott Bosco; Lori A Daiello; Nishant R Shah; Vincent Mor; W John Boscardin; Christine M Berard-Collins; David D Dore; Michael A Steinman
Journal:  Diabetes Obes Metab       Date:  2018-07-22       Impact factor: 6.577

6.  Hyperglycemic effects of hydrochlorothiazide and propranolol. A biochemical and ultrastructural study.

Authors:  G Papaccio; V Esposito
Journal:  Acta Diabetol Lat       Date:  1987 Oct-Dec

Review 7.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 8.  The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years.

Authors:  A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 9.  Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes.

Authors:  K G Dawson; J K McKenzie; S A Ross; J L Chiasson; P Hamet
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

10.  Type of β-blocker use among patients with versus without diabetes after myocardial infarction.

Authors:  Suzanne V Arnold; John A Spertus; Kasia J Lipska; David E Lanfear; Fengming Tang; Anna Grodzinsky; Darren K McGuire; M Odette Gore; Abhinav Goyal; Thomas M Maddox; Mikhail Kosiborod
Journal:  Am Heart J       Date:  2014-06-09       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.